Human B7-H4 ELISA Kit

Code CSB-E15013h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
V-set domain containing T cell activation inhibitor 1
Alternative Names
B7 family member, H4 ELISA Kit; B7 H4 ELISA Kit; B7 homolog 4 ELISA Kit; B7 superfamily member 1 ELISA Kit; B7 superfamily, member 1 ELISA Kit; B7-H4 ELISA Kit; B7h.5 ELISA Kit; B7h4 ELISA Kit; B7S1 ELISA Kit; B7x ELISA Kit; BC032925 ELISA Kit; Immune costimulatory protein B7-H4 ELISA Kit; Immune costimulatory protein B7H4 ELISA Kit; MGC41287 ELISA Kit; PRO1291 ELISA Kit; Protein B7S1 ELISA Kit; RP11 229A19.4 ELISA Kit; T cell costimulatory molecule B7x ELISA Kit; T-cell costimulatory molecule B7x ELISA Kit; V set domain-containing T cell activation inhibitor 1 ELISA Kit; V-set domain-containing T-cell activation inhibitor 1 ELISA Kit; VCTN1 ELISA Kit; Vtcn1 ELISA Kit; VTCN1_HUMAN ELISA Kit
Abbreviation
VTCN1
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, cell culture supernates, tissue homogenates
Detection Range
7.8 ng/mL-500 ng/mL
Sensitivity
1.95 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Immunology
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human B7-H4 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:1Average %95
Range %92-100
1:2Average %90
Range %82-97
1:4Average %92
Range %88-96
1:8Average %87
Range %82-98
Recovery
The recovery of human B7-H4 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9085-97
EDTA plasma (n=4)8984-93
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/mlOD1OD2AverageCorrected
5002.625 2.750 2.688 2.542
2502.100 2.274 2.187 2.041
1251.466 1.463 1.465 1.319
62.50.759 0.797 0.778 0.632
31.250.475 0.461 0.468 0.322
15.60.362 0.366 0.364 0.218
7.80.231 0.245 0.238 0.092
00.142 0.150 0.146  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human VTCN1 ELISA Kit was designed for the quantitative measurement of Human VTCN1 protein in serum, plasma, cell culture supernates, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 7.8 ng/mL-500 ng/mL and the sensitivity is 1.95 ng/mL .

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation.
Gene References into Functions
  1. None of the genotype distributions showed a significant difference from the control group for the rs10801935 polymorphism. We conclude that B7-H4 has the potential to be a useful prognostic marker in urothelial carcinoma. PMID: 28425229
  2. B7-H4/NF-kappaB signaling is involved in the EMT and invasion of bladder cancer cells. PMID: 29391086
  3. The aim of the present work was to evaluate the effectiveness of anti-B7-H4-scFv-CH3 against tumors in vitro and in vivo. ScFv can inhibit signaling pathways to improve immunity by binding with the T lymphocyte negative co-stimulatory factor B7-H4. PMID: 30207312
  4. High B7-H4 expression is associated with phyllodes tumors. PMID: 30486739
  5. Studies suggest that V-set domain containing T cell activation inhibitor 1 protein (B7S1) may represent a very promising candidate to be targeted to treat various tumors. PMID: 30069671
  6. Human Immunodeficiency virus type-1 myeloid derived suppressor cells inhibit cytomegalovirus inflammation through IL-27 and B7-H4. PMID: 28338007
  7. High B7-H4 expression is associated with glioblastoma. PMID: 30159779
  8. Serum B7-H4 detection, either alone or in combination with carbohydrate antigen 125, has an acceptable value in the diagnosis of OC. PMID: 29970702
  9. the findings of this study suggested that B7-H4 may have the potential to be a valuable prognostic marker and a target for individualized therapies for gastric cancer PMID: 29436630
  10. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. PMID: 29235470
  11. B7-H3 protein is expressed in the majority of NSCLCs and is associated with smoking history. High levels of B7-H3 protein have a negative prognostic impact in lung carcinomas. Coexpression of B7-H3 with PD-L1 and B7-H4 is relatively low, suggesting a nonredundant biological role of these targets. PMID: 28539467
  12. When compared to early-stage lung adenocarcinoma, metastatic pleural adenocarcinoma possessed higher level of nuclei membranous B7-H4 and lower cytoplasmic B7-H4 expression. PMID: 28923053
  13. The decrease of B7-H4 expression in salivary glands of Sjogren's syndrome patients contributes to the defect of negatively regulating the inflammation caused by CD4(+) T cells. PMID: 28217953
  14. Preclinical investigation into B7-H4-specific chimeric antigen receptor (CAR) T cells, antibody-mediated blockade of B7-H4, and anti-B7-H4 drug conjugates has shown antitumor efficacy in mouse models. PMID: 28325750
  15. This meta-analysis demonstrated that high B7-H4 expression is an unfavorable prognostic factor in NSCLC. PMID: 28404927
  16. This meta-analysis clarified that high B7-H4 expression in tissue was significantly associated with poor survival in patients with solid tumors. PMID: 27058425
  17. in pulmonary adenocarcinoma presenting with SPN, nuclear membrane localization of B7-H4 within the tumor cells is associated with increased malignancy PMID: 27438152
  18. Study reportes that B7-H3 and B7-H4 are highly expressed in human esophageal cancer tissues and significantly associated with tumor invasion. PMID: 27764786
  19. Results revealed B7-H4 to be associated with poor prognosis in patients with pancreatic cancer liver metastasis. B7-H4 may promote pancreatic cancer metastasis. PMID: 27750217
  20. PD-L1, IDO-1, and B7-H4 are differentially expressed in human lung carcinomas and show limited co-expression. While PD-L1 and IDO-1 are associated with increased tumor-infiltrating lymphoycte and IFN-gamma stimulation, B7-H4 is not. PMID: 27440266
  21. B7-H4 activation on Mphis/microglia in the microenvironment of gliomas is an important immunosuppressive event blocking effective T-cell immune responses. PMID: 27001312
  22. Knockdown of B7-H4 significantly up-regulated 57 miRNAs and down-regulated 14 miRNAs. PMID: 29145206
  23. Increased serum levels of sB7-H4 in early pregnancy in premature rupture of the amniotic membranes cases may indicate the dynamics of the immune response at the feto-maternal interface and, thus, may serve as a predictive marker for this pregnancy complication. PMID: 27302185
  24. our study demonstrates a strong promoting role of B7-H4 in lung tumor growth, progression and metastasis PMID: 28061481
  25. results demonstrated for the first time that miR-125b-5p could regulate the inflammatory state of macrophages via directly targeting B7-H4 PMID: 28754594
  26. B7-H4 is highly expressed in pancreatic cancer, and is an independent predictor of poor prognosis. PMID: 28600225
  27. Evidence of associations between genotypes and Juvenile Idiopathic Arthritis were found for VTCN1, while VTCN1_rs2358820 GA was associated with Uveitis . PMID: 28145159
  28. B7-H4 is highly expressed in human OSCC tissue, and the B7-H4 expression level was associated with the clinicopathological parameters containing pathological grade and lymph node status. PMID: 27383830
  29. High B7-H4 expression is associated with non-Hodgkin lymphoma. PMID: 28246881
  30. B7-H4 is frequently expressed in ovarian serous carcinomas, especially high-grade serous carcinomas, and may represent a novel immunotherapeutic target in this cancer. PMID: 27349304
  31. While PD-L1 expression correlated with MSI and high grade endometrial tumors, B7-H4 expression was independent of grade, histology and immune cell infiltration. PMID: 28347512
  32. the present review highlights the therapeutic potential of targeting B7-H4 in cancer PMID: 28258701
  33. Survival rate of the patients with higher B7-H4 expression was significantly worse than that of the patients with lower B7-H4 expression. PMID: 28412458
  34. Study provides evidence that B7-H4 expression is present in cervical intraepithelial neoplasia and cervical cancer patients and suggests its involvement in cervical cancer progression. PMID: 28260085
  35. this review shows that targeting the B7-H4 molecule may provide a promising potential for anticancer immunotherapy PMID: 27258187
  36. Higher expression of HBx and B7-H4 was correlated with tumor progression of hepatitis B virus-hepatocellular carcinoma, suggesting that B7-H4 may be involved in facilitating HBV-related hepatocarcinogenesis. PMID: 27182163
  37. Aberrant expression of B7-H4 has been identified to correlate with the TNM stage, differentiation degree and lymph node metastasis in patients with HCC. PMID: 27840912
  38. B7-H4 may be overexpressed on the majority of cells in the IDC microenvironment, including macrophages. In vitro experiments revealed that M1 and M2 cells expressed B7-H4. Compared with M1 cells, M2 cells exhibited significantly higher expression levels of B7-H4. PMID: 27430170
  39. wortmannin and rapamycin inhibit B7-H4-mediated tumor immunoresistance through regulating B7-H4 subcellular distribution. Taken together, these results suggest that PI3K/Akt/mTOR inhibitors might be used for adjuvant therapy aimed at inhibition of immune evasion. PMID: 28064317
  40. Unstable cell surface antigens are not suitable as targets for ADCC, and we therefore performed an indirect ADCC-redirecting T-cell cytotoxicity assay to study B7-H4 using polyclonal anti-mouse IgG antibody-mediated linking. PMID: 27632942
  41. Knockdown of B7-H4 increased CD8+ T cell-mediated cytotoxicity in vitro. PMID: 27177355
  42. study provided the first evidence that B7-H4 facilitated esophageal squamous cell carcinoma cell proliferation through promoting IL-6/STAT3 positive loopback pathway activation PMID: 27088889
  43. B7H4 antigen is a negative prognostic marker for pancreatic cancer patients and also seems to express resistance of pancreatic cancer patients to chemotherapy with gemcitabine. PMID: 25924930
  44. B7-H3 and B7-H4 are involved in esophageal squamous cell carcinoma (ESCC) progression and development and their coexpression could be valuable prognostic indicators. PMID: 26411671
  45. study suggest that serum B7-H4 is an independent prognostic indicator for HCC and may be a promising biomarker for early diagnosis as well as disease prognosis of HCC. PMID: 26505457
  46. Data show that disrupted control of costimulation, evidenced by VTCN1 loss in both APCs and pancreatic islets, ultimately results in altered balance of control of immune responses. PMID: 26773144
  47. Studied VTCN1 gene polymorphisms in susceptibility to Breast Cancer. PMID: 25385143
  48. Data indicate that the diagnostic efficiency of V-set domain containing T cell activation inhibitor 1 (sB7-H4) combined carcinoembryonic antigen (CEA) was superior to either sB7-H4 or CEA. PMID: 26301886
  49. In human amniotic fluid stem cells, the negative co-stimulatory molecule B7H4 regulates low immunogenicity, which can provide a modest inflammatory reaction microenvironment for wound repair. PMID: 26101181
  50. In women who underwent elective cesarian section, a significant increase in sB7-H4 serum levels occurred postpartal, while in women who experienced spontaneous onset of labor, there were no differences between prepartal and postpartal levels. PMID: 25907449

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type I membrane protein.
Protein Families
Immunoglobulin superfamily, BTN/MOG family
Tissue Specificity
Overexpressed in breast, ovarian, endometrial, renal cell (RCC) and non-small-cell lung cancers (NSCLC). Expressed on activated T- and B-cells, monocytes and dendritic cells, but not expressed in most normal tissues (at protein level). Widely expressed, i
Database Links

HGNC: 28873

OMIM: 608162

KEGG: hsa:79679

STRING: 9606.ENSP00000358470

UniGene: Hs.546434

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1